Gilead’s tie up with generic cos may not address HIV challenge
US pharma giant Gilead’s partnership with domestic generic manufacturers, aimed at enhancing access to affordable lenacapavir—a groundbreaking therapy for HIV prevention—may fall short in addressing the needs of high-incidence developing countries, and those grappling with rising HIV infections, patent and public health experts say.While the introduction of generics is expected to significantly reduce prices from…
